pyrvinium has been researched along with dasatinib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ang, SH; Asari, K; Bunte, RM; Cheong, JK; Chuah, C; Sun, WT; Teo, B; Than, H; Virshup, DM; Xiang, W; Xu, P | 1 |
1 other study(ies) available for pyrvinium and dasatinib
Article | Year |
---|---|
Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration.
Topics: Adenosine Triphosphate; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Blast Crisis; Casein Kinase I; Cell Line, Tumor; Cell Proliferation; Dasatinib; Humans; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mitochondria; Neoplasm Transplantation; Phosphorylation; Pyrvinium Compounds; RNA Interference | 2015 |